Metabolic Factors Associated with Benign Prostatic Hyperplasia
Top Cited Papers
Open Access
- 1 July 2006
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (7) , 2562-2568
- https://doi.org/10.1210/jc.2005-2799
Abstract
Context: Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear. Obesity and associated abnormalities in glucose homeostasis may play a role in benign prostatic hyperplasia development by influencing prostate growth. Objective: The objective of this study was to determine whether obesity, fasting plasma glucose concentration, and diabetes are associated with radiologically determined prostate enlargement, an objective measure of benign prostatic hyperplasia. Design: This study was a cross-sectional analysis with robust variance estimates to account for multiple measures over time in the same individuals. Setting: This prospective cohort study was composed of community volunteers. Patients: Patients studied were 422 adult men enrolled in The Baltimore Longitudinal Study of Aging. Main Outcome Measurements: Total prostate volume as determined by pelvic magnetic resonance imaging was measured. Results: Among 422 participants, 91 (21.6%) had prostate enlargement (defined as total prostate volume ≥ 40 cc) at first visit. Compared with men of normal weight [body mass index (BMI) < 25 kg/m2], the age-adjusted odds ratio (OR) for prostate enlargement for overweight men (BMI, 25–29.9 kg/m2) was 1.41 (95% CI, 0.84–2.37), for obese men (BMI, 30–34 kg/m2) was 1.27 (95% CI, 0.68–2.39), and for severely obese men (BMI ≥ 35 kg/m2) was 3.52 (95% CI, 1.45–8.56) (P = 0.01). Men with elevated fasting glucose (>110 mg/dl) were more likely to have an enlarged prostate than men with normal fasting glucose (≤110 mg/dl) (OR, 2.98; 95% CI, 1.70–5.23), as were men with a diagnosis of diabetes (OR, 2.25; 95% CI, 1.23–4.11). Conclusions: Obesity, elevated fasting plasma glucose, and diabetes are risk factors for benign prostatic hyperplasia.Keywords
This publication has 73 references indexed in Scilit:
- Optimising the Medical Management of Benign Prostatic HyperplasiaEuropean Urology, 2004
- Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase‐2, Bcl‐2, and cell proliferation in the glandular epitheliumThe Prostate, 2004
- Relationship of serum sex‐steroid hormones and prostate volume in African American menThe Prostate, 2002
- Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of AgingJournal of Urology, 2002
- RACE, ETHNICITY AND BENIGN PROSTATIC HYPERPLASIA IN THE HEALTH PROFESSIONALS FOLLOW-UP STUDYJournal of Urology, 2000
- Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary RetentionEuropean Urology, 2000
- Asymptomatic inflammation and/or infection in benign prostatic hyperplasiaBJU International, 1999
- Accuracy of In-Vivo Assessment of Prostatic Volume by MRI and Transrectal UltrasonographyJournal of Computer Assisted Tomography, 1992
- High‐risk group for benign prostatic hypertrophyThe Prostate, 1983
- HYPERTENSION, DIABETES MELLITUS, AND BLOOD GROUPS IN BENIGN PROSTATIC HYPERTROPHYBritish Journal of Urology, 1966